Phone No.
(780) 450-3957
Capsules and tablets can contain vitamins, minerals, botanical ingredients, nutritional components and other natural health product ingredients with very different analytical requirements.
For that reason, testing should be driven by the formulation, ingredient risks, product specification and quality decision rather than simply by the fact that the product is a capsule or tablet.
Depending on the formulation, testing may include:
PBR Laboratories supports natural health product manufacturers, contract manufacturers, ingredient suppliers, brand owners and quality teams from Edmonton across Alberta, Western Canada and Canada.
The first question is not “Is this a capsule or tablet?” It is “What is in the product, what specification applies, and what must the laboratory result help you decide?”
Applicable products may include:
The analytical program should reflect the actual formulation.
For example:
Botanical capsule
→ microbiology + mycotoxins + heavy metals may be relevant.
Vitamin/mineral tablet
→ composition + microbiology + contaminants may be more relevant.
Multi-ingredient supplement
→ several analytical pathways may need to be considered.
Two capsule products can have completely different risk profiles.
One may contain a refined nutritional ingredient.
Another may contain several raw botanical powders.
Although both are capsules, the appropriate testing may differ because of:
The same principle applies to tablets.
The testing panel should be built around the ingredients and quality objective, not a generic “capsule panel.”
Applicable microbiological testing may include:
The appropriate organisms and limits depend on the product category and specification.
Related Service → Natural Health Product Microbiology Testing
Depending on the product and specification, testing may involve:
Microbial enumeration testing for applicable non-sterile products.
Testing for specified microorganisms.
Microbial enumeration for applicable nutritional and dietary supplement products.
Specified-microorganism testing for applicable nutritional and dietary supplement products.
The correct method should be selected based on the product category, matrix and specification.
A capsule should not automatically be assigned USP <61>/<62> or <2021>/<2022> simply because of its dosage form.
Related Resource → Which USP Microbiology Method Applies to My Natural Health Product?
Botanical capsules can introduce additional considerations because plant-derived materials may be affected by:
Depending on the ingredients, relevant testing may include:
Mycotoxin testing may be relevant where the formulation contains botanical, grain-derived or other agricultural ingredients.
Applicable testing can include:
The decision should be based on ingredient risk rather than dosage form.
A mineral-only tablet, for example, may have a very different mycotoxin-risk profile from a botanical capsule.
Capsules and tablets containing botanical, mineral or naturally sourced ingredients may require consideration of elemental contaminants.
Relevant analytes can include:
Testing may support:
Some capsule and tablet products may require selected compositional testing.
Depending on formulation and analytical scope, this may include:
This is particularly relevant to nutritional formulations rather than products whose primary testing objective is medicinal-ingredient potency.
This distinction should remain explicit.
A nutritional or composition result is not automatically equivalent to medicinal-ingredient potency testing.
Potency testing may require:
PBR should not make a blanket claim that all medicinal ingredients in capsules or tablets can be tested for potency.
Related Resource → Nutritional Analysis vs Medicinal Ingredient Potency Testing
Testing ingredients before manufacturing can support:
A useful workflow is:
Supplier lot → Representative raw-material sample → Applicable testing → Compare with incoming specification → Accept / investigate / take action
Finished-product testing evaluates the manufactured capsule or tablet rather than the incoming ingredient.
This may help answer:
No.
Raw-material testing and finished-product testing answer different questions.
The finished product reflects:
A passing raw-material result should therefore not be treated as proof that every finished-product specification will also be met.
Related Resource → Raw Material Testing vs Finished Product Testing
Sampling should reflect what the result is intended to represent.
Questions include:
The laboratory result applies to the submitted sample.
A small number of units may not automatically support conclusions about an entire production lot.
It depends on the analytical question and method.
For some testing, multiple units may need to be combined to provide sufficient sample material.
For other objectives, unit-to-unit differences may be relevant.
The correct approach should be established before submission based on:
Ask PBR about sample requirements before selecting units for testing.
Multi-ingredient formulations can be affected by blend uniformity before dosage units are manufactured.
Ingredients can differ in:
If a blend is not uniform, individual units may contain different proportions of ingredients.
This makes representative sampling important when the analytical result is intended to support a broader batch decision.
Moisture may be relevant to some capsule and tablet formulations.
Testing can help investigate:
Moisture should be selected because it answers a defined product question—not automatically included in every capsule or tablet panel.
Capsules and tablets may be monitored over time for selected analytical parameters where stability or shelf-life questions are relevant.
Depending on the product, testing may include:
The stability program should be product-specific.
The same time points and analytical parameters should not automatically be applied to every formulation.
A supplier Certificate of Analysis may provide information on:
Independent testing may be useful where the quality team wants to verify selected supplier data.
The strongest approach is:
identify the parameter that matters → confirm method compatibility → test representative incoming material → compare against specification
rather than automatically repeating every line on the supplier certificate.
Related Resource → How to Verify a Supplier Certificate of Analysis
An out-of-specification result does not automatically identify the contamination source.
The investigation may need to consider:
Follow-up testing should address the suspected source rather than simply repeat the final-product test without context.
Related Resource → What to Do After a Failed Natural Health Product Microbiology Result
Review:
Targeted ingredient testing may help determine whether a specific raw material contributes to the result.
Review:
The next analytical step should address the most plausible cause.
Formulation and specification matter more than the words capsule or tablet.
The method should align with product category and specification.
Botanical, mineral and refined ingredients can have different risk profiles.
They are not automatically equivalent.
The finished product answers a different quality question.
Sampling should support the intended conclusion.
The investigation should first consider likely sources.
PBR Laboratories supports capsule and tablet natural health product testing from Edmonton, Alberta.
Alberta manufacturers and quality teams can discuss:
PBR supports natural health product manufacturers throughout Western Canada requiring applicable analytical testing for capsule and tablet products.
The testing approach should follow:
formulation → product risks → specification → representative sample → analytical testing → quality decision
PBR supports Canadian Natural Health Product companies requiring laboratory testing for applicable capsule and tablet formulations.
PBR’s decision-focused approach is to help clients move from:
“What tests are available?”
to:
“Which tests answer the actual quality question for this formulation and finished product?”
Depending on the formulation, testing may include microbiology, composition, heavy metals, mycotoxins, moisture and finished-product quality testing.
The appropriate panel depends on ingredients and specification. Microbiology, selected composition, contaminant and stability-related testing may be relevant.
No. The applicable United States Pharmacopeia method depends on product category, matrix and specification.
Applicable methods may include United States Pharmacopeia <61>, <62>, <2021> and <2022>, depending on the product and specification.
Potentially, where botanical or agricultural ingredients create a relevant mycotoxin risk.
Potentially. Ingredient source, formulation and specification should guide the contaminant-testing program.
No. Composition or nutritional analysis and medicinal-ingredient potency testing may require different methods and analytical objectives.
Raw-material testing may support supplier and incoming-lot decisions. Finished-product testing answers a separate quality question.
No. Manufacturing, blending, additional ingredients, packaging and storage may affect finished-product results.
Sample quantity depends on the analytical method and requested tests. Contact PBR before submission to confirm requirements.
Yes. PBR supports clients throughout Alberta, Western Canada and Canada.